Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
NCT00186355 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 97
Last updated 2012-05-14
Summary
To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
- PROCEDURE
-
high dose chemo then auto hematopoietic cell transplant
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH - lead OTHER
Principal Investigators
-
Robert S Negrin · Stanford University
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 4 Weeks
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-10-31
- Primary Completion
- 2007-03-31
- Completion
- 2010-02-28
Countries
- United States
Study Locations
More Related Trials
-
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00720135 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
NCT00482053 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
NCT00003595 ·Status: COMPLETED ·Phase: PHASE3
-
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
NCT01318317 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
NCT00005089 ·Status: COMPLETED ·Phase: PHASE2
-
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00058292 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
NCT00490529 ·Status: COMPLETED ·Phase: PHASE2
-
HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma
NCT00144092 ·Status: COMPLETED ·Phase: PHASE2
-
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00008021 ·Status: UNKNOWN ·Phase: PHASE1
-
Mantle Irradiation for Hodgkin's Disease
NCT00165269 ·Status: COMPLETED ·Phase: PHASE2
-
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT01745354 ·Status: TERMINATED ·Phase: PHASE1
-
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
NCT00242996 ·Status: COMPLETED ·Phase: PHASE2
-
A Study for Participants With Advanced Cancer
NCT01214629 ·Status: COMPLETED ·Phase: PHASE1
-
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
NCT00186589 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma
NCT00435955 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
NCT00141700 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
NCT05800405 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma
NCT00052923 ·Status: COMPLETED ·Phase: PHASE3
-
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
NCT02051257 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
NCT00499343 ·Status: COMPLETED ·Phase: PHASE2
-
High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas
NCT01148173 ·Status: UNKNOWN ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
NCT01806337 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
NCT00003605 ·Status: WITHDRAWN ·Phase: PHASE2
-
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
NCT02660710 ·Status: COMPLETED ·Phase: PHASE2